I109NCIC CTG Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma
I126A Phase II Study of Letrozole in Patients With Advanced or Recurrent Endometrial Cancer
I142A Phase II Study of SarNU (NSC 364432) in Patients With Malignant Glioma
I145A Phase II Study of ZD6474 in Patients With Relapsed Multiple Myeloma
I146A Phase II Study of Second-Line SarCNU (NSC 364432) in Patients With Recurrent/Metastatic Colorectal Cancer
I148A Phase II Study of OSI-774 (NSC 718781) in Patients With Locally Advanced and/or Metastatic Carcinoma of the Endometrium
I149A Phase II Study Of OSI-774 (NSC 718781) Given In Combination With Carboplatin In Patients With Recurrent Epithelial Ovarian Cancer
I150A Phase II Study of PS-341 (NSC 681239) in Patients With Untreated or Relapsed Mantle Cell Lymphoma
I160A Phase II Study Of CCI-779 In Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer
I161A Phase II Study of Triapine (NSC 663249) in Previously Untreated Patients With Recurrent Renal Cell Carcinoma
I162A Phase I Study Of Temozolomide And RAD001C In Patients With Malignant Glioma
I163A Randomized Phase II Study of Two Different Schedules of RAD001C in Patients With Recurrent/Metastatic Breast Cancer
I164A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel in Advanced Breast Cancer
I166BThis is a Multi-Centre, Open-Label, Dose-Escalating Phase I Clinical Trial of AEG35156 in Combination With Docetaxel in Patients With Solid Tumours
I167Phase II Study of BAY 43-9006 (NSC 724772) in Patients With Hormone Refractory Prostate Cancer
I168A Phase II Study of SB-715992 (NSC 727990) in Patients With Locally Advanced, Recurrent or Metastatic Hepatocellular Carcinoma
I169A Phase II Study of SB-715992 (NSC 727990) in Previously Untreated Patients with Metastatic or Recurrent Malignant Melanoma
I170A Phase I/II Study of GW572016 in Patients With Recurrent Malignant Glioma
I171A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with Standard Chemotherapy Regimens (CT) in Patients with Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer or Other Tumour Types Suitable for Treatment with Capecitabine
I173A Phase I/II Study Of AZD0530 In Combination With Gemcitabine In Patients With Advanced Pancreatic Cancer
I177A Phase I Study Of AT7519M Given Twice Weekly In Patients With Advanced Incurable Malignancy
I181NCIC CTG Phase I Study Of AT9283 Given As A 24 Hour Infusion On Days 1 And 8 Every Three Weeks In Patients With Advanced Incurable Malignancy
I187A Phase I Study Of AZD2281 In Combination With Irinotecan In Patients With Locally Advanced or Metastatic Incurable Colorectal Cancer
I189A Phase II Study of Interleukin-21 (rIL-21) in Patients with Metastatic or Recurrent Malignant Melanoma
I190A Phase I-II Trial of MK-0646, a Monoclonal Antibody Against Insulin-Like Growth Factor-1 Receptor, in Combination with Etoposide and Cisplatin in Extensive Stage Small Cell Lung Cancer.
I191A Phase II Study of AT9283 in Patients with Relapsed or Refractory Multiple Myeloma
I192A Phase II Study of Ridaforolimus in Patients with Metastatic and/or Locally Advanced Recurrent Endometrial Cancer
I193A Phase II Study of AT7519M, A CDK Inhibitor in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia.
I194A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Relapsed Mantle Cell Lymphoma
I195A Phase II Study of SB939 in Patients with Recurrent or Metastatic Castration Resistant Prostate Cancer
I196A Phase I/II Study of Foretinib in Patients with Previously Treated Non-Small Cell Lung Cancer Receiving Standard Erlotinib Therapy (IND.196)
I197A Phase II Study of Foretinib in Patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer.
I198A Phase I/II Study of Foretinib in Combination with Lapatinib in Patients with Human Epidermal Growth Factor Receptor 2(HER2)Over-Expressing Metastatic Breast Cancer
I199A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients with Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix.
I200A Phase II Study of SB939 in Patients with Translocation-Associated Recurrent/Metastatic Sarcomas.
I202A Randomized Phase II Study of Interleukin-21 (rIL-21) versus Dacarbazine (DTIC) in Patients with Metastatic or Recurrent Melanoma
I204A Phase II Study of PX-866 in Patients with Glioblastoma Multiforme at Time of First Relapse or Progression.
I205A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer (CRPC).
I206A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours.
I207A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma
I208Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination with Panitumumab in Patients with Metastatic or Advanced RAS-Wild Type Colorectal Cancer.
I209A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer
I210A Randomized Phase II Study of Reolysin in Combination with FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients with Metastatic Colorectal Cancer.
I211A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy.
I213A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer
I214A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients with Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours
I215A Phase Ib Study of Selumetinib in Patients with Previously Treated or Untreated Advanced/Metastatic NSCLC Who are Receiving Standard Chemotherapy Regimens.
I216Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia
I219A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-Based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
I221A Dose-Ranging Study of IPH2201 in Patients with Gynecologic Malignancies
I222A Phase I Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients with Previously Treated Glioblastoma Multiforme
I223A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer
I226A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given with or without Standard Chemotherapy Regimens
I227A Phase II/III Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma
I228A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours
I229A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients with HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab
I231A Phase I Study of CX5461
I232A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer
I234Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol
I235A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination with Ipilimumab for the Treatment of Patients with Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay
I236A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination with Weekly Paclitaxel in Patients with Advanced/Metastatic HER2-Negative Breast Cancer
I237A Phase II Study of CFI-400945 in Patients with Advanced/Metastatic Breast Cancer
I238A Phase II Study of Durvalumab
Substudy A: In Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity
Substudy B: For Continued Treatment (+/-) Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
I239A Phase II Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer (TNBC)
I240An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)
I241A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
I242Neoadjuvant Platform Trial in Patients with Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
I243A Phase II Study of RP-6306 in Patients with Advanced Cancer
I244A Phase 2 Study of Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary Central Nervous System Lymphoma
Inventory
Show Tissue Samples
| Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
| IND | I109 | 17 | 0 | 14 | 14 |
| IND | I126 | 33 | 8 | 12 | 12 |
| IND | I142 | 10 | 2 | 4 | 6 |
| IND | I145 | 18 | 2 | 1 | 3 |
| IND | I146 | 18 | 9 | 5 | 12 |
| IND | I148 | 34 | 16 | 29 | 29 |
| IND | I149 | 50 | 26 | 48 | 48 |
| IND | I150 | 30 | 2 | 4 | 4 |
| IND | I160 | 62 | 33 | 54 | 56 |
| IND | I161 | 19 | 12 | 4 | 13 |
| IND | I162 | 32 | 6 | 25 | 27 |
| IND | I163 | 49 | 6 | 47 | 47 |
| IND | I164 | 15 | 1 | 13 | 14 |
| IND | I166B | 27 | 0 | 0 | 0 |
| IND | I167 | 28 | 10 | 16 | 26 |
| IND | I168 | 15 | 3 | 2 | 4 |
| IND | I169 | 17 | 8 | 1 | 8 |
| IND | I170 | 24 | 5 | 22 | 22 |
| IND | I171 | 50 | 17 | 1 | 18 |
| IND | I173 | 34 | 7 | 15 | 22 |
| IND | I177 | 34 | 5 | 4 | 5 |
| IND | I181 | 35 | 4 | 4 | 4 |
| IND | I187 | 26 | 14 | 16 | 23 |
| IND | I189 | 40 | 6 | 33 | 39 |
| IND | I190 | 12 | 6 | 2 | 8 |
| IND | I191 | 8 | 4 | 0 | 4 |
| IND | I192 | 35 | 16 | 34 | 34 |
| IND | I193 | 7 | 0 | 0 | 0 |
| IND | I194 | 12 | 0 | 0 | 0 |
| IND | I195 | 32 | 20 | 21 | 32 |
| IND | I196 | 31 | 18 | 21 | 25 |
| IND | I197 | 47 | 41 | 44 | 44 |
| IND | I198 | 19 | 17 | 19 | 19 |
| IND | I199 | 38 | 21 | 36 | 36 |
| IND | I200 | 24 | 2 | 1 | 2 |
| IND | I202 | 64 | 32 | 55 | 60 |
| IND | I204 | 34 | 21 | 28 | 33 |
| IND | I205 | 68 | 44 | 18 | 60 |
| IND | I206 | 137 | 87 | 134 | 135 |
| IND | I207 | 17 | 10 | 12 | 16 |
| IND | I208 | 22 | 13 | 18 | 18 |
| IND | I209 | 85 | 48 | 65 | 66 |
| IND | I210 | 109 | 75 | 100 | 103 |
| IND | I211 | 166 | 81 | 142 | 146 |
| IND | I213 | 81 | 73 | 76 | 80 |
| IND | I214 | 56 | 56 | 54 | 56 |
| IND | I215 | 39 | 18 | 38 | 38 |
| IND | I216 | 14 | 0 | 0 | 0 |
| IND | I219 | 62 | 1 | 1 | 2 |
| IND | I221 | 59 | 56 | 40 | 58 |
| IND | I222 | 15 | 7 | 12 | 13 |
| IND | I223 | 57 | 0 | 3 | 3 |
| IND | I226 | 153 | 69 | 122 | 122 |
| IND | I227 | 520 | 234 | 491 | 492 |
| IND | I228 | 175 | 63 | 172 | 172 |
| IND | I229 | 15 | 14 | 15 | 15 |
| IND | I231 | 41 | 15 | 34 | 36 |
| IND | I232 | 52 | 48 | 51 | 51 |
| IND | I234 | 549 | 105 | 50 | 126 |
| IND | I235 | 107 | 0 | 4 | 4 |
| IND | I236 | 37 | 23 | 32 | 36 |
| IND | I237 | 76 | 24 | 66 | 69 |
| IND | I238 | Open Trial | 4 | 8 | 12 |
| IND | I239 | 15 | 9 | 15 | 15 |
| IND | I240 | Open Trial | 20 | 13 | 20 |
| IND | I241 | Open Trial | 34 | 29 | 53 |
| IND | I242 | 4 | 3 | 3 | 3 |
| IND | I243 | Open Trial | 12 | 32 | 32 |
| IND | I244 | Open Trial | 7 | 4 | 8 |
(Core size is 0.6 mm)
Show
Fluid Samples| Disease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
| IND | I109 | 17 | 0 | 0 |
| IND | I126 | 33 | 0 | 0 |
| IND | I142 | 10 | 0 | 0 |
| IND | I145 | 18 | 0 | 0 |
| IND | I146 | 18 | 0 | 0 |
| IND | I148 | 34 | 0 | 0 |
| IND | I149 | 50 | 0 | 0 |
| IND | I150 | 30 | 0 | 0 |
| IND | I160 | 62 | 0 | 0 |
| IND | I161 | 19 | 0 | 0 |
| IND | I162 | 32 | 0 | 0 |
| IND | I163 | 49 | 0 | 0 |
| IND | I164 | 15 | 0 | 0 |
| IND | I166B | 27 | 0 | 0 |
| IND | I167 | 28 | 0 | 0 |
| IND | I168 | 15 | 0 | 0 |
| IND | I169 | 17 | 0 | 0 |
| IND | I170 | 24 | 0 | 0 |
| IND | I171 | 50 | 1 | 1 |
| IND | I173 | 34 | 0 | 0 |
| IND | I177 | 34 | 0 | 0 |
| IND | I181 | 35 | 0 | 0 |
| IND | I187 | 26 | 1 | 2 |
| IND | I189 | 40 | 0 | 0 |
| IND | I190 | 12 | 0 | 0 |
| IND | I191 | 8 | 0 | 0 |
| IND | I192 | 35 | 0 | 0 |
| IND | I193 | 7 | 0 | 0 |
| IND | I194 | 12 | 0 | 0 |
| IND | I195 | 32 | 1 | 1 |
| IND | I196 | 31 | 1 | 8 |
| IND | I197 | 47 | 2 | 18 |
| IND | I198 | 19 | 1 | 4 |
| IND | I199 | 38 | 0 | 0 |
| IND | I200 | 24 | 1 | 1 |
| IND | I202 | 64 | 1 | 22 |
| IND | I204 | 34 | 0 | 0 |
| IND | I205 | 68 | 1 | 2 |
| IND | I206 | 137 | 1 | 15 |
| IND | I207 | 17 | 1 | 4 |
| IND | I208 | 22 | 1 | 6 |
| IND | I209 | 85 | 1 | 13 |
| IND | I210 | 109 | 1 | 30 |
| IND | I211 | 166 | 1 | 18 |
| IND | I213 | 81 | 1 | 32 |
| IND | I214 | 56 | 0 | 0 |
| IND | I215 | 39 | 1 | 0 |
| IND | I216 | 14 | 0 | 0 |
| IND | I219 | 62 | 0 | 0 |
| IND | I221 | 59 | 1 | 2 |
| IND | I222 | 15 | 0 | 0 |
| IND | I223 | 57 | 0 | 0 |
| IND | I226 | 153 | 1 | 26 |
| IND | I227 | 520 | 1 | 21 |
| IND | I228 | 175 | 1 | 14 |
| IND | I229 | 15 | 1 | 3 |
| IND | I231 | 41 | 1 | 2 |
| IND | I232 | 52 | 1 | 5 |
| IND | I234 | 549 | 0 | 0 |
| IND | I235 | 107 | 0 | 0 |
| IND | I236 | 37 | 1 | 2 |
| IND | I237 | 76 | 0 | 0 |
| IND | I238 | Open Trial | 0 | 0 |
| IND | I239 | 15 | 0 | 0 |
| IND | I240 | Open Trial | 0 | 0 |
| IND | I241 | Open Trial | 0 | 0 |
| IND | I242 | 4 | 0 | 0 |
| IND | I243 | Open Trial | 0 | 0 |
| IND | I244 | Open Trial | 0 | 0 |
| Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
| IND | I109 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I126 | 33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I142 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I145 | 18 | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 |
| IND | I146 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I148 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I149 | 50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I150 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I160 | 62 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I161 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I162 | 32 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I163 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I164 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I166B | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I167 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I168 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I169 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I170 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I171 | 50 | 0 | 0 | 0 | 0 | 31 | 0 | 25 | 0 |
| IND | I173 | 34 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 |
| IND | I177 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I181 | 35 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
| IND | I187 | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I189 | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I190 | 12 | 10 | 0 | 0 | 0 | 0 | 12 | 0 | 0 |
| IND | I191 | 8 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| IND | I192 | 35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I193 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I194 | 12 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| IND | I195 | 32 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I196 | 31 | 31 | 0 | 0 | 0 | 31 | 31 | 0 | 0 |
| IND | I197 | 47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I198 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I199 | 38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I200 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I202 | 64 | 42 | 0 | 0 | 0 | 60 | 60 | 0 | 0 |
| IND | I204 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I205 | 68 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I206 | 137 | 1 | 0 | 120 | 0 | 0 | 0 | 0 | 0 |
| IND | I207 | 17 | 0 | 0 | 0 | 0 | 17 | 15 | 0 | 0 |
| IND | I208 | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I209 | 85 | 51 | 0 | 0 | 0 | 46 | 53 | 0 | 0 |
| IND | I210 | 109 | 57 | 0 | 0 | 0 | 52 | 60 | 1 | 0 |
| IND | I211 | 166 | 164 | 0 | 0 | 0 | 155 | 165 | 0 | 0 |
| IND | I213 | 81 | 69 | 0 | 0 | 0 | 64 | 70 | 0 | 0 |
| IND | I214 | 56 | 48 | 0 | 0 | 0 | 0 | 56 | 46 | 0 |
| IND | I215 | 39 | 32 | 0 | 0 | 0 | 37 | 37 | 0 | 0 |
| IND | I216 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I219 | 62 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I221 | 59 | 53 | 0 | 0 | 0 | 53 | 54 | 0 | 0 |
| IND | I222 | 15 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| IND | I223 | 57 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I226 | 153 | 0 | 0 | 0 | 0 | 0 | 150 | 0 | 0 |
| IND | I227 | 520 | 4 | 0 | 0 | 0 | 375 | 395 | 0 | 0 |
| IND | I228 | 175 | 0 | 0 | 0 | 0 | 135 | 0 | 0 | 0 |
| IND | I229 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I231 | 41 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I232 | 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I234 | 549 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I235 | 107 | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 0 |
| IND | I236 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I237 | 76 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I238 | Open Trial | 0 | 0 | 0 | 0 | 13 | 13 | 0 | 0 |
| IND | I239 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IND | I240 | Open Trial | 20 | 0 | 0 | 0 | 20 | 0 | 0 | 0 |
| IND | I241 | Open Trial | 60 | 0 | 0 | 0 | 60 | 0 | 0 | 0 |
| IND | I242 | 4 | 4 | 0 | 0 | 0 | 4 | 1 | 0 | 0 |
| IND | I243 | Open Trial | 27 | 0 | 0 | 0 | 27 | 0 | 0 | 0 |
| IND | I244 | Open Trial | 10 | 0 | 0 | 0 | 10 | 0 | 0 | 0 |